Works matching DE "GEFITINIB"

Results: 818

Gefitinib Facilitates Bone Fracture Healing via Inhibition of the EGFR Pathway and Counteracting SOX9-driven Bone Metabolic Reprogramming.

Published in:

In Vivo, 2025, v. 39, n. 3, p. 1394, doi. 10.21873/invivo.13942

By:

NING XU;
GONGWU YUAN;
WENBO ZENG;
XIMING LIU;
MA WAN;
SUYANG XU;
YIKANG BI;
HAI HU;
YAFENG XU;
SHENGHUI LAN

Publication type:

Article

Novel Silver Nanocomposites as Effective Antitumor Agents.

Published in:

Macromolecular Symposia, 2023, v. 409, n. 1, p. 1, doi. 10.1002/masy.202200142

By:

Gorbunova, M. N.;
Beloglazova, Yu. A.

Publication type:

Article

Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier-Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor.

Published in:

Advanced Functional Materials, 2014, v. 24, n. 35, p. 5482, doi. 10.1002/adfm.201400456

By:

Li, Da;
Li, Yongbin;
Xing, Haibo;
Guo, Junling;
Ping, Yuan;
Tang, Guping

Publication type:

Article

Fabrication of β-cyclodextrin-mediated single bimolecular inclusion complex: characterization, molecular docking, in-vitro release and bioavailability studies for gefitinib and simvastatin conjugate.

Published in:

Journal of Pharmacy & Pharmacology, 2017, v. 69, n. 10, p. 1304, doi. 10.1111/jphp.12769

By:

Basak, Souvik;
Mondal, Sandip;
Dey, Suddhasattya;
Bhattacharya, Plaban;
Saha, Achintya;
Deep Punetha, Vinay;
Abbas, Ali;
Gopal Sahoo, Nanda

Publication type:

Article

Busting the Breast Cancer with AstraZeneca's Gefitinib.

Published in:

Advances in Pharmacological & Pharmaceutical Sciences, 2023, p. 1, doi. 10.1155/2023/8127695

By:

Chemmalar, S.;
Intan Shameha, A. R.;
Che Abdullah, Che Azurahanim;
Ab Razak, Nor Asma;
Yusof, Loqman Mohamad;
Ajat, Mokrish;
Chan, Kim Wei;
Abu Bakar Zakaria, Md Zuki

Publication type:

Article

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

Published in:

NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00170-7

By:

Yoshizawa, Takahiro;
Uchibori, Ken;
Araki, Mitsugu;
Matsumoto, Shigeyuki;
Ma, Biao;
Kanada, Ryo;
Seto, Yosuke;
Oh-hara, Tomoko;
Koike, Sumie;
Ariyasu, Ryo;
Kitazono, Satoru;
Ninomiya, Hironori;
Takeuchi, Kengo;
Yanagitani, Noriko;
Takagi, Satoshi;
Kishi, Kazuma;
Fujita, Naoya;
Okuno, Yasushi;
Nishio, Makoto;
Katayama, Ryohei

Publication type:

Article

NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01892-w

By:

Zhen, Shuman;
Jia, Yunlong;
Zhao, Yan;
Wang, Jiali;
Zheng, Boyang;
Liu, Tianxu;
Duan, Yuqing;
Lv, Wei;
Wang, Jiaqi;
Xu, Fan;
Liu, Yueping;
Zhang, Yi;
Liu, Lihua

Publication type:

Article

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer.

Published in:

Cell Death Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41420-023-01476-0

By:

Han, Shuyan;
Tian, Zhihua;
Tian, Huifang;
Han, Haibo;
Zhao, Jun;
Jiao, Yanna;
Wang, Chunli;
Hao, Huifeng;
Wang, Shan;
Fu, Jialei;
Xue, Dong;
Sun, Hong;
Li, Pingping

Publication type:

Article

Synthesis, characterization and in vitro antiproliferative effects of isosteviol derivatives.

Published in:

Journal of Asian Natural Products Research, 2024, v. 26, n. 7, p. 812, doi. 10.1080/10286020.2024.2324082

By:

Qi, Xin-Xin;
Wang, Pan-Pan;
Cui, Lan-Tian;
Jin, Mei;
Zhao, Long-Xuan;
Li, Gao

Publication type:

Article

Design, synthesis and anti-tumor activity of asiatic acid derivatives as VEGF inhibitors.

Published in:

Journal of Asian Natural Products Research, 2023, v. 25, n. 4, p. 357, doi. 10.1080/10286020.2022.2093194

By:

Meng, Yan-Qiu;
Wu, Yue-Jiao;
Kuai, Zhen-Yu;
Ma, Jun-Jiao;
Wang, Zan;
Meng, Bei-Bei;
Wang, Zhi-Qi

Publication type:

Article

Synthesis and antitumor activity evaluation of new asiatic acid derivatives.

Published in:

Journal of Asian Natural Products Research, 2012, v. 14, n. 9, p. 844, doi. 10.1080/10286020.2012.699961

By:

Meng, Yan-Qiu;
Li, Yun-Yun;
Li, Feng-Qing;
Song, Yan-Ling;
Wang, Hai-Feng;
Chen, Hong;
Cao, Bo

Publication type:

Article

Evaluation of Anticancer Activity of 76 Plant Species Collected in Andalusia (Spain) against Lung Cancer Cells.

Published in:

Plants (2223-7747), 2023, v. 12, n. 18, p. 3275, doi. 10.3390/plants12183275

By:

Jiménez-González, Víctor;
Benítez, Guillermo;
Pastor, Julio Enrique;
López-Lázaro, Miguel;
Calderón-Montaño, José Manuel

Publication type:

Article

Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: a pilot study.

Published in:

International Journal of Palliative Nursing, 2014, v. 20, n. 3, p. 135, doi. 10.12968/ijpn.2014.20.3.135

By:

Shu-Yi Wang;
Chun-Ming Tsai;
Chia-Chin Lin

Publication type:

Article

Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance.

Published in:

BioMed Research International, 2019, p. 1, doi. 10.1155/2019/3129748

By:

Li, Xin-ying;
Huang, Li-tang;
Wu, Jia-qi;
He, Ming-fang;
Zhu, Su-hua;
Zhan, Ping;
Lv, Tang-feng;
Song, Yong

Publication type:

Article

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer.

Published in:

Cancer Biology & Medicine, 2022, v. 19, n. 8, p. 1173, doi. 10.20892/j.issn.2095-3941.2021.0130

By:

Ting He;
Yinglei Gao;
Yanfen Fang;
Yangming Zhang;
Shuwei Zhang;
Fajun Nan;
Jian Ding;
Yi Chen

Publication type:

Article

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.

Published in:

Cancer Biology & Medicine, 2014, v. 11, n. 4, p. 270

By:

Guo-Hao Xia;
Yun Zeng;
Ying Fang;
Shao-Rong Yu;
Li Wang;
Mei-Qi Shi;
Wei-Li Sun;
Xin-En Huang;
Jia Chen;
Ji-Feng Feng

Publication type:

Article

Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes.

Published in:

Experimental Dermatology, 2022, v. 31, n. 6, p. 918, doi. 10.1111/exd.14538

By:

Oh, Jang‐Hee;
Hur, Woojune;
Li, Na;
Jo, Seong Jin

Publication type:

Article

On chip synthesis of a pH sensitive gefitinib anticancer drug nanocarrier based on chitosan/alginate natural polymers.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-51483-z

By:

Alizadeh, Hossein;
Ahmadi, Mazaher;
Heydari Shayesteh, Omid

Publication type:

Article

Regorafenib Adverse Drug Reactions among Patients in King Abdullah Medical City; A Chart Review Study.

Published in:

International Journal of Pharmaceutical Research & Allied Sciences, 2022, v. 11, n. 4, p. 24, doi. 10.51847/IexPv4xRns

By:

Baz, Hasan Ahmed H.;
Halawani, Saeed H.;
Abdulaziz, Ibrahim;
Ali, Majid;
Baz, Nhal Ahmed;
Jafal, Mohammed;
Saleh, Khaldoun

Publication type:

Article

Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1218480

By:

Xiao Li;
Yong-Li Gu;
Xu-Chao Liu;
Zeng-Xian Sun;
Ying Sun

Publication type:

Article

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1171302

By:

Tingting Lu;
Yufan Huang;
Zhongjie Cai;
Wangchun Lin;
Xiaoxiao Chen;
Ruijia Chen;
Yingying Hu

Publication type:

Article

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1241130

By:

Yena Gan;
Fenghao Shi;
He Zhu;
Sheng Han;
Duoduo Li

Publication type:

Article

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1212313

By:

Wei Chen;
Julian Miao;
Ying Wang;
Wenzhong Xing;
Xiumei Xu;
Rui Wu

Publication type:

Article

Cellular photo(geno)toxicity of gefitinib after biotransformation.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1208075

By:

El Ouardi, Meryem;
Tamarit, Lorena;
Vayá, Ignacio;
Miranda, Miguel A.;
Andreu, Inmaculada

Publication type:

Article

A new sample preparation method for the determination of acyclovir by RP-HPLC: application to a drug-drug interaction study between gefitinib and acyclovir in rats.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2021, v. 30, n. 6, p. 495, doi. 10.5246/jcps.2021.06.038

By:

Ying Li;
Zhou Wen;
Yongling Liu;
Zhibing Zhao;
Lei Wang;
Zeneng Cheng

Publication type:

Article

Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2021, v. 30, n. 3, p. 253, doi. 10.5246/jcps.2021.03.021

By:

Shaohong Luo;
Liangliang Dong;
Yiyuan Li;
Dan Xu;
Min Chen

Publication type:

Article

Concomitant administration of gastric acid suppression might attenuates the clinical efficacy of gefitinib: a single cancer center retrospective study.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2020, v. 29, n. 3, p. 192, doi. 10.5246/jcps.2020.03.016

By:

Zihan Guo;
Qiong Du;
Xuan Ye;
Feifei Gao;
Yufang You;
Bo Yu;
Qing Zhai

Publication type:

Article

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Published in:

Lung Cancer: Targets & Therapy, 2017, v. 8, p. 109, doi. 10.2147/LCTT.S119644

By:

Santarpia, Mariacarmela;
Liguori, Alessia;
Karachaliou, Niki;
Gonzalez-Cao, Maria;
Daffinà, Maria Grazia;
D'Aveni, Alessandro;
Marabello, Grazia;
Altavilla, Giuseppe;
Rosell, Rafael

Publication type:

Article

Gefitinib frequently induces liver damagein patients with lung adenocarcinoma previously treated by chemotherapy.

Published in:

Lung Cancer: Targets & Therapy, 2013, v. 4, p. 9, doi. 10.2147/LCTT.S45172

By:

Yasoo Sugiura;
Etsuo Nemoto;
Osamu Kawai;
Yasuyuki Ohkubo;
Hisae Fusegawa;
Shizuka Kaseda

Publication type:

Article

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Published in:

Lung Cancer: Targets & Therapy, 2012, v. 3, p. 91, doi. 10.2147/LCTT.S12959

By:

Berghmans, Thierry;
Remmelink, Myriam;
Awada, Ahmad

Publication type:

Article

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

Published in:

Cancer Research & Treatment, 2024, v. 56, n. 1, p. 48, doi. 10.4143/crt.2023.453

By:

Ki Hyeong Lee;
Byoung Chul Cho;
Myung-Ju Ahn;
Yun-Gyoo Lee;
Youngjoo Lee;
Jong-Seok Lee;
Joo-Hang Kim;
Young Joo Min;
Gyeong-Won Lee;
Sung Sook Lee;
Kyung-Hee Lee;
Yoon Ho Ko;
Byoung Yong Shim;
Sang-We Kim;
Sang Won Shin;
Jin-Hyuk Choi;
Dong-Wan Kim;
Eun Kyung Cho;
Keon Uk Park;
Jin-Soo Kim

Publication type:

Article

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 2, p. 479, doi. 10.4143/crt.2022.1344

By:

Hyun Ae Jung;
Sehhoon Park;
Se-Hoon Lee;
Jin Seok Ahn;
Myung-Ju Ahn;
Jong-Mu Sun

Publication type:

Article

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.

Published in:

Cancer Research & Treatment, 2019, v. 51, n. 2, p. 502, doi. 10.4143/crt.2018.117

By:

Youjin Kim;
Se-Hoon Lee;
Jin Seok Ahn;
Myung-Ju Ahn;
Keunchil Park;
Jong-Mu Sun

Publication type:

Article

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

Published in:

Cancer Research & Treatment, 2016, v. 48, n. 2, p. 458, doi. 10.4143/crt.2015.135

By:

Jin Hyoung Kang;
Myung-Ju Ahn;
Dong-Wan Kim;
Eun Kyung Cho;
Joo-Hang Kim;
Sang Won Shin;
Xin Wang;
Jong Seok Kim;
Mauro Orlando;
Keunchil Park

Publication type:

Article

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2016, v. 48, n. 1, p. 80, doi. 10.4143/crt.2014.307

By:

Young Saing Kim;
Eun Kyung Cho;
Hyun Sun Woo;
Junshik Hong;
Hee Kyung Ahn;
Inkeun Park;
Sun Jin Sym;
Sun Young Kyung;
Shin Myung Kang;
Jeong-Woong Park;
Sung Hwan Jeong;
Jinny Park;
Jae Hoon Lee;
Dong Bok Shin

Publication type:

Article

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.

Published in:

Cancer Research & Treatment, 2016, v. 48, n. 1, p. 88, doi. 10.4143/crt.2014.201

By:

Seung-Hoon Beom;
Dong-Wan Kim;
Sung Hoon Sim;
Bhumsuk Keam;
Jin Hyun Park;
Jeong-Ok Lee;
Tae Min Kim;
Se-Hoon Lee;
Dae Seog Heo

Publication type:

Article

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution.

Published in:

Cancer Research & Treatment, 2013, v. 45, n. 3, p. 178, doi. 10.4143/crt.2013.45.3.178

By:

Bhumsuk Keam;
Dong-Wan Kim;
Jin Hyun Park;
Jeong-Ok Lee;
Tae Min Kim;
Se-Hoon Lee;
Doo Hyun Chung;
Dae Seog Heo

Publication type:

Article

A landscape of response to drug combinations in non-small cell lung cancer.

Published in:

Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39528-9

By:

Nair, Nishanth Ulhas;
Greninger, Patricia;
Zhang, Xiaohu;
Friedman, Adam A.;
Amzallag, Arnaud;
Cortez, Eliane;
Sahu, Avinash Das;
Lee, Joo Sang;
Dastur, Anahita;
Egan, Regina K.;
Murchie, Ellen;
Ceribelli, Michele;
Crowther, Giovanna S.;
Beck, Erin;
McClanaghan, Joseph;
Klump-Thomas, Carleen;
Boisvert, Jessica L.;
Damon, Leah J.;
Wilson, Kelli M.;
Ho, Jeffrey

Publication type:

Article

Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.

Published in:

Cellular Oncology (2211-3428), 2022, v. 45, n. 5, p. 913, doi. 10.1007/s13402-022-00696-3

By:

Choi, Seul-Ki;
Kim, Minsuh;
Lee, Haeseung;
Kwon, Youngjoo;
Cha, Hyuk-Jin;
Jang, Se Jin;
Na, Younghwa;
Lee, Yun-Sil

Publication type:

Article

Drug combination screening as a translational approach toward an improved drug therapy for chordoma.

Published in:

Cellular Oncology (2211-3428), 2021, v. 44, n. 6, p. 1231, doi. 10.1007/s13402-021-00632-x

By:

Scheipl, Susanne;
Barnard, Michelle;
Lohberger, Birgit;
Zettl, Richard;
Brcic, Iva;
Liegl-Atzwanger, Bernadette;
Rinner, Beate;
Meindl, Claudia;
Fröhlich, Eleonore

Publication type:

Article

Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial–mesenchymal transition through targeting major vault protein (MVP).

Published in:

Cellular Oncology (2211-3428), 2021, v. 44, n. 1, p. 109, doi. 10.1007/s13402-020-00556-y

By:

Lou, Lei;
Wang, Juan;
Lv, Fengzhu;
Wang, Guohui;
Li, Yuehong;
Xing, Lingxiao;
Shen, Haitao;
Zhang, Xianghong

Publication type:

Article

ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors.

Published in:

Cancers, 2024, v. 16, n. 20, p. 3501, doi. 10.3390/cancers16203501

By:

Kimura, Ryo;
Adachi, Yuta;
Hirade, Kentaro;
Kisoda, Satoru;
Yanase, Shogo;
Shibata, Noriko;
Ishii, Makoto;
Fujiwara, Yutaka;
Yamaguchi, Rui;
Fujita, Yasuko;
Hosoda, Waki;
Ebi, Hiromichi

Publication type:

Article

The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer.

Published in:

Cancers, 2024, v. 16, n. 6, p. 1170, doi. 10.3390/cancers16061170

By:

Ma, Yunxia;
Nenkov, Miljana;
Berndt, Alexander;
Abubrig, Mohamed;
Schmidt, Martin;
Sandhaus, Tim;
Huber, Otmar;
Clement, Joachim H.;
Lang, Susanne M.;
Chen, Yuan;
Gaßler, Nikolaus

Publication type:

Article

Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients with Driver Mutations.

Published in:

Cancers, 2024, v. 16, n. 2, p. 464, doi. 10.3390/cancers16020464

By:

Tachibana, Taimei;
Matsuura, Yosuke;
Ninomiya, Hironori;
Ichinose, Junji;
Nakao, Masayuki;
Okumura, Sakae;
Nishio, Makoto;
Ikeda, Norihiko;
Mun, Mingyon

Publication type:

Article

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation.

Published in:

Cancers, 2022, v. 14, n. 19, p. 4709, doi. 10.3390/cancers14194709

By:

Liao, Tingting;
Deng, Jingjing;
Chen, Wenjuan;
Xu, Juanjuan;
Yang, Guanghai;
Zhou, Mei;
Lv, Zhilei;
Wang, Sufei;
Song, Siwei;
Tan, Xueyun;
Yin, Zhengrong;
Li, Yumei;
Jin, Yang

Publication type:

Article

Integrative Analysis of Angiogenesis-Related Long Non-Coding RNA and Identification of a Six-DEARlncRNA Signature Associated with Prognosis and Therapeutic Response in Esophageal Squamous Cell Carcinoma.

Published in:

Cancers, 2022, v. 14, n. 17, p. 4195, doi. 10.3390/cancers14174195

By:

Cao, Shasha;
Wang, Xiaomin;
Liu, Xiaohui;
Li, Junkuo;
Duan, Lijuan;
Gao, Zhaowei;
Lun, Shumin;
Zhu, Yanju;
Yang, Haijun;
Zhang, Hao;
Zhou, Fuyou

Publication type:

Article

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.

Published in:

Cancers, 2022, v. 14, n. 6, p. 1512, doi. 10.3390/cancers14061512

By:

Choi, Yu-ra;
Cho, Youngnam;
Park, Seog-Yun;
Kim, Sunshin;
Shin, Myungsun;
Choi, Yongdoo;
Shin, Dong Hoon;
Han, Ji-Youn;
Lee, Youngjoo

Publication type:

Article

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI.

Published in:

Cancers, 2022, v. 14, n. 4, p. 977, doi. 10.3390/cancers14040977

By:

Chang, John Wen-Cheng;
Huang, Chen-Yang;
Fang, Yueh-Fu;
Chang, Ching-Fu;
Yang, Cheng-Ta;
Kuo, Chih-Hsi Scott;
Hsu, Ping-Chih;
Wu, Chiao-En

Publication type:

Article

Microglial Cytokines Induce Invasiveness and Proliferation of Human Glioblastoma through Pyk2 and FAK Activation.

Published in:

Cancers, 2021, v. 13, n. 24, p. 6160, doi. 10.3390/cancers13246160

By:

Nuñez, Rebeca E.;
del Valle, Miguel Mayol;
Ortiz, Kyle;
Almodovar, Luis;
Kucheryavykh, Lilia

Publication type:

Article

Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase ® the WHO Global Database of Individual Case Safety Reports.

Published in:

Cancers, 2021, v. 13, n. 23, p. 5907, doi. 10.3390/cancers13235907

By:

Crosnier, Alexandre;
Abbara, Chadi;
Cellier, Morgane;
Lagarce, Laurence;
Babin, Marina;
Bourneau-Martin, Delphine;
Briet, Marie

Publication type:

Article